

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNOUNCEMENT OF THE AUDITED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022

References are made to the announcement of Link-Asia International MedTech Group Limited (the “**Company**”) dated 31 March 2023 in relation to announcement of the annual results for the year ended 31 December 2022 (the “**Results Announcement**”). Unless otherwise stated, capitalised terms used in this announcement shall have the same meaning as those defined in the Results Announcement.

In addition to the information provided in the Results Announcement, the Board would like to provide further information in relation to the purchases, sales or redemption of Company’s listed securities during the year ended 31 December 2022.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

There was no purchase, sale or redemption of the Company’s listed securities by the Company or any of the subsidiaries during the year ended 31 December 2022.

Save as disclosed above, the contents of the Results Announcement remain unchanged.

By Order of the Board
Link-Asia International MedTech Group Limited
Lin Dailian
Chairman and Executive Director

Hong Kong, 3 April 2023

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Liu Zhiwei, Mr. Li Yinxiang and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.